The extended-release formulation of tramadol was shown to be as effective as buprenorphine and more effective than clonidine for treating symptoms of opioid withdrawal.
Once-weekly subcutaneous buprenorphine injections block the euphoric effects of opioids and suppress opioid withdrawal in patients with opioid use disorder.
Early pharmacologic intervention for opioid use disorder after diagnosis is crucial to prevent relapse and overdose in adolescents and young adults.
Discrepancies in Subjective vs Objective Sleep in Patients Receiving Buprenorphine for Opioid Use DisorderJune 20, 2017
Patients receiving buprenorphine maintenance therapy for their opioid use disorder may have impaired sleep, despite their reports of improved quality and duration of sleep.
Changes in several measures of pain in patients suspected of opioid-induced hyperalgesia were observed after transitioning from opioids to buprenorphine.
Substance Use Disorder is a chronic medical condition, and should be treated like one.
Teenagers with prescription opioid exposures are more likely to have health care facility admission and serious medical outcomes than younger children.
Pennsylvania has adopted a multipronged approach to address the opioid crisis.
Buprenorphine/naloxone treatment initiated in the emergency department and prolonged for 10 weeks in primary care improved treatment engagement and reduced opioid use compared with referral or brief intervention.
Patients addicted to opioids treated in a hospital emergency department do better when they receive medication to reduce opioid cravings.
An 8-day detoxification process using low-dose oral naltrexone showed superior efficacy to the standard 15-day approach that uses an agonist taper leading to induction with extended-release naltrexone
Throughout 2016, the FDA has announced requirements for manufacturers to create new product labeling information for a variety of opioid medications.
The initiatives include guidelines and recommendations for CRNAs, physicians, and policymakers.
The researchers found that novice prescribers cited insufficient access to substance abuse counseling for patients, as well as insufficient access to more experienced prescribers, as reasons for not treating more patients.
There is a lot of opportunity to improve on what can be offered to patients.
Buprenorphine implants could help improve relapse prevention in patients who are currently maintaining abstinence with sublingual buprenorphine
When tolerated, buprenorphine is effective for diabetic peripheral neuropathic pain
Improved delivery method for buprenorphine
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioids Might Not Be the Answer to the Opioid Crisis
- Paracetamol Superior to Placebo for Osteoarthritis Knee Pain
- Fracture Risk in Children Predicted by New Bone Density Assessment
- Collaborative Care Superior to Standard Care for Opioid Use Disorder
- Gabapentinoids: Evaluating the Benefits for Chronic Low Back Pain